A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.

Cancer Med · 2019 · PMC6718621 · PMID 31347292

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

From a safety standpoint, the DSMB identified no unexpected safety signals but noted worse RR and PFS in the tarextumab treatment group and a strong trend toward lack of OS benefit in the tarextumab treatment group, irrespective of Notch3 expression levels.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.